These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 30091169

  • 1. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ, Marx N.
    Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 11; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P, Acharya T.
    Am J Cardiovasc Drugs; 2019 Jun 11; 19(3):249-257. PubMed ID: 30767126
    [Abstract] [Full Text] [Related]

  • 5. The kidney and cardiovascular outcome trials.
    Bloomgarden Z.
    J Diabetes; 2018 Feb 11; 10(2):88-89. PubMed ID: 29031006
    [Abstract] [Full Text] [Related]

  • 6. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
    Kaul S.
    Diabetes Care; 2017 Jul 11; 40(7):821-831. PubMed ID: 28637887
    [Abstract] [Full Text] [Related]

  • 7. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I, Grigoropoulou P, Liberopoulos E, Liatis S, Kokkinos A, Tentolouris N.
    Curr Med Chem; 2018 Jul 11; 25(13):1549-1566. PubMed ID: 28554326
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P.
    Diabetologia; 2019 Mar 11; 62(3):357-369. PubMed ID: 30607467
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH, Barry AR, Koshman SL.
    Am J Health Syst Pharm; 2017 Jul 01; 74(13):970-976. PubMed ID: 28483748
    [Abstract] [Full Text] [Related]

  • 10. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
    Giugliano D, Maiorino MI, Bellastella G, Esposito K.
    Endocrine; 2018 May 01; 60(2):224-228. PubMed ID: 28895030
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
    Cheng JWM, Badreldin HA, Patel DK, Bhatt SH.
    Curr Med Res Opin; 2017 Jun 01; 33(6):985-992. PubMed ID: 28097882
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K.
    Diabetes Obes Metab; 2019 Aug 01; 21(8):1790-1800. PubMed ID: 30969018
    [Abstract] [Full Text] [Related]

  • 19. [Outcome studies on SGLT-2 inhibitors].
    Seufert J, Laubner K.
    Internist (Berl); 2019 Sep 01; 60(9):903-911. PubMed ID: 31375850
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.